Revolution Medicines, Inc. (Nasdaq: RVMD) presented Phase 1/2 clinical trial data for zoldonrasib, its oral RAS(ON) G12D-selective inhibitor, in two ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA